Cargando…

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Massarotti, L., Branca, A., Pavan, L., Maroccia, A., Cavarretta, C.A., Ruocco, V., Zatta, I., Scapinello, G., Piazza, F., D’Amore, F., Lessi, F., Gurrieri, C., Zambello, R., Trentin, L., Berno, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171715/ http://dx.doi.org/10.1097/01.HS9.0000936236.83735.8b

Ejemplares similares

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

P1111: WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (≥75-YEAR-OLD): DESCRIPTION OF CLINICAL FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN ACADEMIC CENTER
por: Danesin, Nicolò, et al.
Publicado: (2023)

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH
por: Manni, S., et al.
Publicado: (2022)

Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital
por: Danesin, Nicolò, et al.
Publicado: (2023)

CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
por: Fregnani, Anna, et al.
Publicado: (2022)

PB2261: LINEZOLID AS A SAFE ANTIMICROBIAL AGENT IN THROMBOCYTOPENIC PATIENTS UNDERGOING CHEMOTHERAPY FOR HEMATOLOGIC MALIGNANCIES
por: Angotzi, F., et al.
Publicado: (2022)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

P1076: A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN’S LYMPHOMA IN THE PET-GUIDED ERA
por: Cellini, A., et al.
Publicado: (2022)

Cyclophosphamide as a first-line therapy in LGL leukemia
por: Moignet, A, et al.
Publicado: (2014)

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
por: Piazza, Francesco, et al.
Publicado: (2010)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

The effect of cyclophosphamide on MSV-H oncogenesis.
por: Branca, M., et al.
Publicado: (1977)

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS
por: Cellini, Alessandro, et al.
Publicado: (2023)

Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
por: Piazza, Francesco, et al.
Publicado: (2022)

Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
por: Barilà, Gregorio, et al.
Publicado: (2020)

Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen
por: Kumar, Santosh, et al.
Publicado: (2010)

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.
por: Lessi, Federica, et al.
Publicado: (2023)

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival
por: Trimarco, Valentina, et al.
Publicado: (2015)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
por: van Warmerdam, L. J., et al.
Publicado: (1996)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases
por: Zuluaga, Andres F, et al.
Publicado: (2006)

Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission.
por: Pizzolo, G., et al.
Publicado: (1988)

Applied Bayesian statistical studies in biology and medicine
por: Bacco, M, et al.
Publicado: (2004)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
por: Manni, Sabrina, et al.
Publicado: (2013)

Thermochemotherapy-induced resistance to cyclophosphamide.
por: Urano, M., et al.
Publicado: (1988)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

P1251: BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION
por: Ceccato, J., et al.
Publicado: (2022)

HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen
por: Frezzato, Federica, et al.
Publicado: (2012)

Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.
por: Trentin, L., et al.
Publicado: (1994)

Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa
por: Wagh, Himanshu, et al.
Publicado: (2022)

Effects of the induction of hepatic microsomal metabolism on the toxicity of cyclophosphamide.
por: Gurtoo, H. L., et al.
Publicado: (1985)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
por: Paplham, Pamela, et al.
Publicado: (2014)

Bases filosóficas, pedagógicas, epistemológicas y conceptuales de la Didáctica de la Matemática /
por: D'Amore, Bruno
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_amqm00m37ul9o3v0s1jma9v3ou